二甲双胍
微生物群
肠道微生物群
肠道菌群
医学
炎症
2型糖尿病
免疫系统
糖尿病
先天免疫系统
免疫学
生物信息学
生物
内分泌学
作者
Sri Nitya Reddy Induri,Payalben Kansara,Scott C. Thomas,Fangxi Xu,Deepak Saxena,Xin Li
出处
期刊:Annual Review of Pharmacology and Toxicology
[Annual Reviews]
日期:2021-08-24
卷期号:62 (1): 85-108
被引量:43
标识
DOI:10.1146/annurev-pharmtox-051920-093829
摘要
Metformin has been extensively used for the treatment of type 2 diabetes, and it may also promote healthy aging. Despite its widespread use and versatility, metformin's mechanisms of action remain elusive. The gut typically harbors thousands of bacterial species, and as the concentration of metformin is much higher in the gut as compared to plasma, it is plausible that microbiome-drug-host interactions may influence the functions of metformin. Detrimental perturbations in the aging gut microbiome lead to the activation of the innate immune response concomitant with chronic low-grade inflammation. With the effectiveness of metformin in diabetes and antiaging varying among individuals, there is reason to believe that the gut microbiome plays a role in the efficacy of metformin. Metformin has been implicated in the promotion and maintenance of a healthy gut microbiome and reduces many age-related degenerative pathologies. Mechanistic understanding of metformin in the promotion of a healthy gut microbiome and aging will require a systems-level approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI